PD-L1 as a biomarker of response to immune-checkpoint inhibitors

By D. Doroshow, S. Bhalla, M. Beasley, L. Sholl, K. Kerr, S. Gnjatic, I. Wistuba, David L. Rimm, Ming-Sound Tsao, F. Hirsch. Nature Reviews Clinical Oncology, 2021

1,271 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/1b594d9ad62c7f83fb855b5eb7c20030fc186705

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Brambilla
2. W. Travis
3. M. Beasley
4. A. Nicholson
5. K. Kerr
6. M. Noguchi
7. S. Dacic
8. P. V. Van Schil

Citations in the corpus

• NF-κB in biology and targeted therapy: new insights and translational implications (2024, background): “518,532 Intriguingly, the NF-κ B pathways have recently been raised as promising molecular targets to enhance the antitumor activity of checkpoint inhibitors.”
• The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. (2021, background): “Unlike genomic driver alterations which should be present in all tumor cells, PD-L1 protein expression is often heterogeneous within a tumor, and it could be dynamic and influenced by previous treatment.(44) In”
• Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “Both tumour and immune cells can express PD-L1 which is a useful biomarker in predicting response to anti-PD-1/PD-L1 antibodies in some patients with different types of cancer [53].”